scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1031267755 |
P356 | DOI | 10.1186/SCRT336 |
P8608 | Fatcat ID | release_rpquch7ltnahnbalwmrpql2jai |
P932 | PMC publication ID | 3854702 |
P698 | PubMed publication ID | 24406104 |
P5875 | ResearchGate publication ID | 259650589 |
P50 | author | Paula Laranjeira | Q58924808 |
Cláudia Lobato da Silva | Q82271615 | ||
Ana Henriques | Q45911497 | ||
Artur Paiva | Q47805899 | ||
Isabel Velada | Q49804796 | ||
Joaquim M Cabral | Q57837606 | ||
Mário Grãos | Q58392050 | ||
P2093 | author name string | Andreia Ribeiro | |
António Martinho | |||
Pedro Andrade | |||
Carla M P Cardoso | |||
Francisco Santos | |||
Hélder Trindade | |||
Cristiana Leite | |||
Sandrine Mendes | |||
Mluísa Pais | |||
P2860 | cites work | Mesenchymal stem cells avoid allogeneic rejection | Q21245658 |
Regulation of interleukin-12 expression in human monocytes: selective priming by interferon-gamma of lipopolysaccharide-inducible p35 and p40 genes | Q24317746 | ||
Immunomodulation by mesenchymal stem cells: a potential therapeutic strategy for type 1 diabetes | Q24644691 | ||
The interleukin 12 p40 gene promoter is primed by interferon gamma in monocytic cells | Q24678409 | ||
Multilineage potential of adult human mesenchymal stem cells | Q27860737 | ||
Human mesenchymal stem cells modulate allogeneic immune cell responses | Q28288692 | ||
Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli | Q29618769 | ||
Stem cells: attributes, cycles, spirals, pitfalls and uncertainties. Lessons for and from the crypt | Q29618968 | ||
Human mesenchymal stem cells modulate B-cell functions | Q29620705 | ||
Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. | Q30157916 | ||
Mesenchymal stem cells repress Th17 molecular program through the PD-1 pathway. | Q31101562 | ||
Pro-inflammatory cytokines, IFNgamma and TNFalpha, influence immune properties of human bone marrow and Wharton jelly mesenchymal stem cells differentially | Q33528988 | ||
IL-6-dependent PGE2 secretion by mesenchymal stem cells inhibits local inflammation in experimental arthritis | Q33769303 | ||
Long-lasting inhibitory effects of fetal liver mesenchymal stem cells on T-lymphocyte proliferation | Q33916474 | ||
Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells. | Q34007524 | ||
B7-H4 Treatment of T Cells Inhibits ERK, JNK, p38, and AKT Activation | Q34124940 | ||
B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes | Q34128389 | ||
Mesenchymal stromal cells: current understanding and clinical status | Q34234464 | ||
Aggregatibacter actinomycetemcomitans GroEL protein promotes conversion of human CD4+ T cells into IFNγ IL10 producing Tbet+ Th1 cells | Q34477877 | ||
The different immunoregulatory functions on dendritic cells between mesenchymal stem cells derived from bone marrow of patients with low-risk or high-risk myelodysplastic syndromes | Q34613086 | ||
Immunomodulatory properties of human adult and fetal multipotent mesenchymal stem cells | Q35166506 | ||
Utility of flow cytometric detection of CD69 expression as a rapid method for determining poly- and oligoclonal lymphocyte activation. | Q35226762 | ||
Mesenchymal stem cells impair in vivo T-cell priming by dendritic cells | Q35409468 | ||
Mesenchymal stem cell effects on T-cell effector pathways. | Q35558505 | ||
Adipose-derived adult stem cells: isolation, characterization, and differentiation potential. | Q35567830 | ||
CD69 is independently prognostic in chronic lymphocytic leukemia: a comprehensive clinical and biological profiling study. | Q35717883 | ||
Mesenchymal stromal cells. Biology of adult mesenchymal stem cells: regulation of niche, self-renewal and differentiation | Q35769073 | ||
Human adipose-derived stem cells impair natural killer cell function and exhibit low susceptibility to natural killer-mediated lysis | Q35964770 | ||
Immunomodulatory effect of mesenchymal stem cells on B cells | Q36105639 | ||
TGF-β signaling via Smad4 drives IL-10 production in effector Th1 cells and reduces T-cell trafficking in EAE | Q36340416 | ||
Adult stem cells in the treatment of autoimmune diseases | Q36508132 | ||
Human mesenchymal stem cells inhibit antibody production induced in vitro by allostimulation | Q60313622 | ||
CD69, CD25, and HLA-DR activation antigen expression on CD3+ lymphocytes and relationship to serum TNF-α, IFN-γ, and sIL-2R levels in aging | Q61054681 | ||
Toll-Like Receptors 3 and 4 Are Expressed by Human Bone Marrow-Derived Mesenchymal Stem Cells and Can Inhibit Their T-Cell Modulatory Activity by Impairing Notch Signaling | Q61638150 | ||
Mesenchymal Stem Cell-Mediated Immunosuppression Occurs via Concerted Action of Chemokines and Nitric Oxide | Q61645540 | ||
Interferon-γ-dependent inhibition of B cell activation by bone marrow-derived mesenchymal stem cells in a murine model of systemic lupus erythematosus | Q61657757 | ||
Accessory cell-derived helper signals in human T-cell activation with phytohemagglutinin: induction of interleukin 2-responsiveness by interleukin 6, and production of interleukin 2 by interleukin 1 [corrected] | Q67264509 | ||
Similar co-stimulation requirements of CD4+ and CD8+ primary T helper cells: role of IL-1 and IL-6 in inducing IL-2 secretion and subsequent proliferation | Q68054966 | ||
Comparative effects of tumor necrosis factor-alpha and IL-1 beta on mitogen-induced T cell activation | Q70051189 | ||
Inhibition of human B cell responsiveness by prostaglandin E2 | Q70161872 | ||
Regulation of human B cell proliferation by prostaglandin E2 | Q70225368 | ||
Suppressed PHA activation of T lymphocytes in simulated microgravity is restored by direct activation of protein kinase C | Q74530628 | ||
Functional aspects of cord blood lymphocytes response to polyclonal and allogeneic activation | Q77142499 | ||
Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells | Q79208808 | ||
Differentiation potential of mesenchymal stem cells of different origin | Q80161547 | ||
Immunosuppressive effects of mesenchymal stem cells: involvement of HLA-G | Q80714885 | ||
Semaphorin-3A is expressed by tumor cells and alters T-cell signal transduction and function | Q82097189 | ||
Mesenchymal stem cells | Q83591416 | ||
Subpopulation composition and activation of T lymphocytes during coculturing with mesenchymal stromal cells in medium with different O(2) content | Q83751058 | ||
Characterization and functionality of the CD200-CD200R system during mesenchymal stromal cell interactions with T-lymphocytes | Q84105212 | ||
Modulated expression of adhesion molecules and galectin-1: role during mesenchymal stromal cell immunoregulatory functions | Q84460527 | ||
Adipose-tissue-derived and Wharton's jelly-derived mesenchymal stromal cells suppress lymphocyte responses by secreting leukemia inhibitory factor | Q84514926 | ||
Human multipotent mesenchymal stromal cells use galectin-1 to inhibit immune effector cells | Q84579882 | ||
The negative co-signaling molecule b7-h4 is expressed by human bone marrow-derived mesenchymal stem cells and mediates its T-cell modulatory activity | Q84595031 | ||
[Effect of mesenchymal stem cells on expression of CD69 in cord blood CIK/NK cells and quantity ratio of T regulatory cells in CIK/NK cell culture] | Q84747907 | ||
Human MSC suppression correlates with cytokine induction of indoleamine 2,3-dioxygenase and bystander M2 macrophage differentiation | Q84968409 | ||
Opposing effect of mesenchymal stem cells on Th1 and Th17 cell polarization according to the state of CD4+ T cell activation | Q85121641 | ||
Mesenchymal stem cells in immunoregulation | Q36547852 | ||
Mesenchymal stem cells derived from human induced pluripotent stem cells modulate T-cell phenotypes in allergic rhinitis | Q36563846 | ||
Immunoregulatory function of mesenchymal stem cells | Q36609696 | ||
Immune regulation by mesenchymal stem cells: two sides to the coin | Q36703067 | ||
Indoleamine 2,3-dioxygenase in immune suppression and cancer. | Q36737697 | ||
Immunomodulatory properties of mesenchymal stromal cells | Q36896799 | ||
Inhibition of T cell and natural killer cell function by adenosine and its contribution to immune evasion by tumor cells (Review). | Q37091784 | ||
Soluble mediators from mesenchymal stem cells suppress T cell proliferation by inducing IL-10. | Q37241672 | ||
Relationship between T-lymphocyte cytokine levels and sero-response to hepatitis B vaccines | Q37277444 | ||
Mesenchymal stem cells suppress B-cell terminal differentiation. | Q37355322 | ||
Human umbilical cord mesenchymal stem cells and the treatment of spinal cord injury. | Q37383664 | ||
Mesenchymal stem cells: a new strategy for immunosuppression and tissue repair | Q37724579 | ||
Immunosuppression by mesenchymal stem cells: mechanisms and clinical applications | Q37760962 | ||
Immunological aspects of allogeneic mesenchymal stem cell therapies | Q37780764 | ||
Mesenchymal Stem Cells: Mechanisms of Inflammation | Q37809081 | ||
Immunomodulatory properties of mesenchymal stem cells: cytokines and factors. | Q37939411 | ||
CD4⁺T cells: differentiation and functions | Q37999790 | ||
On the interactions between mesenchymal stem cells and regulatory T cells for immunomodulation in transplantation | Q38013107 | ||
CD200/CD200R paired potent inhibitory molecules regulating immune and inflammatory responses; Part I: CD200/CD200R structure, activation, and function. | Q38018612 | ||
Isolation and animal serum free expansion of human umbilical cord derived mesenchymal stromal cells (MSCs) and endothelial colony forming progenitor cells (ECFCs) | Q38272382 | ||
Cord-blood-derived mesenchymal stromal cells downmodulate CD4+ T-cell activation by inducing IL-10-producing Th1 cells | Q39296574 | ||
Human placenta-derived mesenchymal stem cells suppress T cell proliferation and support the culture expansion of cord blood CD34⁺ cells: a comparison with human bone marrow-derived mesenchymal stem cells | Q39529152 | ||
Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity. | Q39531156 | ||
Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype. | Q39698715 | ||
Mesenchymal stem cells protect breast cancer cells through regulatory T cells: role of mesenchymal stem cell-derived TGF-beta | Q39716192 | ||
Brief report--human embryonic stem cell-derived mesenchymal progenitors possess strong immunosuppressive effects toward natural killer cells as well as T lymphocytes | Q39920526 | ||
Mesenchymal Stem Cells - Sources and Clinical Applications | Q40138962 | ||
Transplantation of placenta-derived mesenchymal stem cells in type 2 diabetes: a pilot study | Q40321403 | ||
Interactions between human mesenchymal stem cells and natural killer cells | Q40385365 | ||
Immune regulatory properties of multipotent mesenchymal stromal cells: Where do we stand? | Q41807857 | ||
Multiplex analysis of cytokines, chemokines, growth factors, MMP-9 and TIMP-1 produced by human bone marrow, adipose tissue, and placental mesenchymal stromal cells | Q42503938 | ||
Umbilical cord-derived mesenchymal stromal cells modulate monocyte function to suppress T cell proliferation. | Q42845624 | ||
Prostaglandin E2 plays a key role in the immunosuppressive properties of adipose and bone marrow tissue-derived mesenchymal stromal cells. | Q42922142 | ||
Mesenchymal stromal cells use PGE2 to modulate activation and proliferation of lymphocyte subsets: Combined comparison of adipose tissue, Wharton's Jelly and bone marrow sources | Q42974571 | ||
Ex vivo expansion of human mesenchymal stem cells: a more effective cell proliferation kinetics and metabolism under hypoxia. | Q43216186 | ||
Galectin-1 and semaphorin-3A are two soluble factors conferring T-cell immunosuppression to bone marrow mesenchymal stem cell | Q43249326 | ||
Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation | Q44317237 | ||
Evidence for the involvement of galectin-3 in mesenchymal stem cell suppression of allogeneic T-cell proliferation | Q44599908 | ||
Allogenic mesenchymal stem cell transplantation ameliorates nephritis in lupus mice via inhibition of B-cell activation | Q44985029 | ||
Mesenchymal stem cells inhibit the expression of CD25 (interleukin-2 receptor) and CD38 on phytohaemagglutinin-activated lymphocytes | Q45024308 | ||
Cell contact, prostaglandin E(2) and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+CD25(High) forkhead box P3+ regulatory T cells. | Q45834735 | ||
Fetal BM-derived mesenchymal stem cells promote the expansion of human Th17 cells, but inhibit the production of Th1 cells | Q45844247 | ||
Mesenchymal stromal cell-derived CCL2 suppresses plasma cell immunoglobulin production via STAT3 inactivation and PAX5 induction | Q45880435 | ||
Comparison of immunomodulatory properties of mesenchymal stem cells derived from adult human tissues. | Q45927700 | ||
Mesenchymal stromal cells promote or suppress the proliferation of T lymphocytes from cord blood and peripheral blood: the importance of low cell ratio and role of interleukin-6. | Q45946882 | ||
The effect of mesenchymal stem cells on the viability, proliferation and differentiation of B-lymphocytes. | Q46010474 | ||
Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms | Q46390299 | ||
The immunosuppressive effects of human bone marrow-derived mesenchymal stem cells target T cell proliferation but not its effector function | Q46576236 | ||
Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. | Q46939105 | ||
Mesenchymal stem cells from human bone marrow or adipose tissue differently modulate mitogen-stimulated B-cell immunoglobulin production in vitro | Q47923725 | ||
Quantification and immunophenotypic characterization of bone marrow and umbilical cord blood mesenchymal stem cells by multicolor flow cytometry. | Q50453265 | ||
Genetically modified adipose tissue-derived mesenchymal stem cells overexpressing CXCR4 display increased motility, invasiveness, and homing to bone marrow of NOD/SCID mice. | Q50524510 | ||
Human mesenchymal stem cells from adipose tissue and amnion influence T-cells depending on stimulation method and presence of other immune cells. | Q50543459 | ||
Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. | Q50767537 | ||
Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. | Q52008649 | ||
Mesenchymal stromal cells inhibit Th17 but not regulatory T-cell differentiation. | Q53281677 | ||
Mesenchymal stem cells stimulate antibody secretion in human B cells. | Q53563416 | ||
Human mesenchymal stem cells derived from induced pluripotent stem cells down-regulate NK-cell cytolytic machinery. | Q54462820 | ||
Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. | Q54671130 | ||
Mesenchymal stromal cells up-regulate CD39 and increase adenosine production to suppress activated T-lymphocytes | Q56787014 | ||
Generation of CD4+ or CD8+ regulatory T cells upon mesenchymal stem cell-lymphocyte interaction | Q56901258 | ||
Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype | Q56902900 | ||
P433 | issue | 5 | |
P921 | main subject | umbilical cord mesenchymal stem cell | Q107296590 |
P304 | page(s) | 125 | |
P577 | publication date | 2013-10-15 | |
P1433 | published in | Stem Cell Research & Therapy | Q14390536 |
P1476 | title | Mesenchymal stem cells from umbilical cord matrix, adipose tissue and bone marrow exhibit different capability to suppress peripheral blood B, natural killer and T cells | |
P478 | volume | 4 |
Q34601943 | Adipose-derived stromal cells promote allograft tolerance induction |
Q36272379 | Basic Fibroblast Growth Factor Inhibits Apoptosis and Promotes Proliferation of Adipose-Derived Mesenchymal Stromal Cells Isolated from Patients with Type 2 Diabetes by Reducing Cellular Oxidative Stress |
Q33872923 | Bone Marrow Mesenchymal Stem Cells Inhibit the Function of Dendritic Cells by Secreting Galectin-1. |
Q50628184 | Bone Marrow Mesenchymal Stromal Cells Induce Proliferative, Cytokinic and Molecular Changes During the T Cell Response: The Importance of the IL-10/CD210 Axis. |
Q90319531 | Bone marrow derived mesenchymal stem cells ameliorate inflammatory response in an in vitro model of familial hemophagocytic lymphohistiocytosis 2 |
Q52994215 | Bone marrow mesenchymal stem cells suppressing activation of allogeneic cytokine-induced killer/natural killer cells either by direct or indirect interaction. |
Q34803754 | Changes in immunological profile of allogeneic mesenchymal stem cells after differentiation: should we be concerned? |
Q50190841 | Characterization of Sox9-overexpressing human umbilical cord blood-derived mesenchymal stem cells-based engineered cartilage both in vitro and in vivo |
Q57169681 | Chronic Niche Inflammation in Endometriosis-Associated Infertility: Current Understanding and Future Therapeutic Strategies |
Q64109237 | Comparative study of the neural differentiation capacity of mesenchymal stromal cells from different tissue sources: An approach for their use in neural regeneration therapies |
Q26822005 | Comparing the Immunomodulatory Properties of Bone Marrow, Adipose Tissue, and Birth-Associated Tissue Mesenchymal Stromal Cells |
Q64084614 | Comparison of Mesenchymal Stromal Cells From Different Origins for the Treatment of Graft-vs.-Host-Disease in a Humanized Mouse Model |
Q65000505 | Comparison of therapeutic effects of different mesenchymal stem cells on rheumatoid arthritis in mice. |
Q58702140 | Current Strategies to Generate Human Mesenchymal Stem Cells In Vitro |
Q64113492 | Delivery of oncolytic vaccinia virus by matched allogeneic stem cells overcomes critical innate and adaptive immune barriers |
Q34428273 | Differentiation of human umbilical cord matrix mesenchymal stem cells into neural-like progenitor cells and maturation into an oligodendroglial-like lineage |
Q49177046 | Does the Mesenchymal Stem Cell Source Influence Smooth Muscle Regeneration in Tissue-Engineered Urinary Bladders? |
Q64966372 | Effect of Comedications and Endotoxins on Mesenchymal Stem Cell Secretomes, Migratory and Immunomodulatory Capacity. |
Q35562203 | Effect of human bone marrow mesenchymal stromal cells on cytokine production by peripheral blood naive, memory, and effector T cells |
Q50248506 | Effects of local administration of allogenic adipose tissue-derived mesenchymal stem cells on functional recovery in experimental traumatic brain injury |
Q54989352 | Genetic contribution to mesenchymal stem cell dysfunction in systemic lupus erythematosus. |
Q28071840 | Genetically modified mesenchymal stromal cells in cancer therapy |
Q39803218 | Growth suppression effect of human mesenchymal stem cells from bone marrow, adipose tissue, and Wharton's jelly of umbilical cord on PBMCs |
Q43576209 | Haploidentical hematopoietic stem cell transplant with umbilical cord-derived multipotent mesenchymal cell infusion for the treatment of high-risk acute leukemia in children |
Q40548665 | Human Bone Marrow-Derived Mesenchymal Stromal Cells Differentially Inhibit Cytokine Production by Peripheral Blood Monocytes Subpopulations and Myeloid Dendritic Cells. |
Q36805987 | Human Liver Stem Cells Suppress T-Cell Proliferation, NK Activity, and Dendritic Cell Differentiation |
Q35580306 | Human Umbilical Cord Mesenchymal Stem Cells Inhibit the Function of Allogeneic Activated Vγ9Vδ2 T Lymphocytes In Vitro |
Q33805077 | Human adipose-derived mesenchymal stem cells alleviate obliterative bronchiolitis in a murine model via IDO. |
Q49587686 | Immunological impact of Wharton's Jelly mesenchymal stromal cells and natural killer cell co-culture |
Q94503661 | Immunomodulatory Effect of Adipose-Derived Stem Cells: The Cutting Edge of Clinical Application |
Q38775114 | Immunomodulatory effects of bone marrow versus adipose tissue-derived mesenchymal stromal cells on NK cells: implications in the transplantation setting |
Q27026892 | Immunoregulation by mesenchymal stem cells: biological aspects and clinical applications |
Q26770107 | Immunotolerant Properties of Mesenchymal Stem Cells: Updated Review |
Q35078827 | In vitro augmentation of mesenchymal stem cells viability in stressful microenvironments : In vitro augmentation of mesenchymal stem cells viability |
Q58776448 | Infrapatellar Fat Pad-Derived Stem Cell-Based Regenerative Strategies in Orthopedic Surgery |
Q42291750 | In Vitro Generation of Vascular Wall-Resident Multipotent Stem Cells of Mesenchymal Nature from Murine Induced Pluripotent Stem Cells |
Q42362354 | Membrane particles generated from mesenchymal stromal cells modulate immune responses by selective targeting of pro-inflammatory monocytes |
Q33569871 | Mesenchymal Stem Cell Therapy Protects Lungs from Radiation-Induced Endothelial Cell Loss by Restoring Superoxide Dismutase 1 Expression |
Q88884604 | Mesenchymal Stem Cell-Based Therapy for Cardiovascular Disease: Progress and Challenges |
Q64108180 | Mesenchymal Stem Cells Improve Rheumatoid Arthritis Progression by Controlling Memory T Cell Response |
Q28354224 | Mesenchymal Stem Cells as Therapeutic Candidates for Halting the Progression of Diabetic Nephropathy |
Q90459409 | Mesenchymal Stem Cells for the Treatment of Liver Disease: Present and Perspectives |
Q57300327 | Mesenchymal Stem Cells in Primary Sjögren's Syndrome: Prospective and Challenges |
Q26746104 | Mesenchymal Stem and Progenitor Cells in Normal and Dysplastic Hematopoiesis-Masters of Survival and Clonality? |
Q46374324 | Mesenchymal stem cell therapy: A promising cell-based therapy for treatment of myocardial infarction |
Q26770191 | Mesenchymal stem cells and immunomodulation: current status and future prospects |
Q28828416 | Mesenchymal stem cells in corneal neovascularization: Comparison of different application routes |
Q59790772 | Mesenchymal stem cells in preclinical cancer cytotherapy: a systematic review |
Q38733373 | Mesenchymal stromal cell therapy for the treatment of intestinal ischemia: Defining the optimal cell isolate for maximum therapeutic benefit |
Q37661559 | Mesenchymal stromal cells as vehicles of tetravalent bispecific Tandab (CD3/CD19) for the treatment of B cell lymphoma combined with IDO pathway inhibitor D-1-methyl-tryptophan |
Q49924219 | Mesenchymal stromal cells of the bone marrow and natural killer cells: cell interactions and cross modulation. |
Q48234353 | Molecular and Cellular Mechanisms Involved in Mesenchymal Stem Cell-Based Therapy of Inflammatory Bowel Diseases. |
Q89557788 | Multidose intramuscular allogeneic adipose stem cells decrease the severity of canine atopic dermatitis: A pilot study |
Q34786543 | Potential therapeutic effect of the secretome from human uterine cervical stem cells against both cancer and stromal cells compared with adipose tissue stem cells |
Q64249676 | Production of Mesenchymal Stem Cells Through Stem Cell Reprogramming |
Q36440734 | Propranolol and Mesenchymal Stromal Cells Combine to Treat Traumatic Brain Injury |
Q90558489 | Regenerative therapy by endometrial mesenchymal stem cells in thin endometrium with repeated implantation failure. A novel strategy |
Q39017821 | Review article: mesenchymal stromal cell therapy for inflammatory bowel diseases |
Q91783625 | Similarities and differences between mesenchymal stem/progenitor cells derived from various human tissues |
Q38648343 | Stem cells - biological update and cell therapy progress |
Q91637582 | The Achievements and Challenges of Mesenchymal Stem Cell-Based Therapy in Inflammatory Bowel Disease and Its Associated Colorectal Cancer |
Q103829366 | The Chemokine Receptors Ccr5 and Cxcr6 Enhance Migration of Mesenchymal Stem Cells into the Degenerating Retina |
Q47229258 | The Clinical Applications of Endometrial Mesenchymal Stem Cells |
Q45913373 | The Immunomodulatory Effects of Mesenchymal Stem Cell Polarization within the Tumor Microenvironment Niche. |
Q26779265 | The Long Path of Human Placenta, and Its Derivatives, in Regenerative Medicine |
Q90151295 | The Safe and Efficacious Use of Secretome From Fibroblasts and Adipose-derived (but not Bone Marrow-derived) Mesenchymal Stem Cells for Skin Therapeutics |
Q26781292 | The immune response of stem cells in subretinal transplantation |
Q41869342 | The injury progression of T lymphocytes in a mouse model with subcutaneous injection of a high dose of sulfur mustard. |
Q35206489 | The multiple functional roles of mesenchymal stem cells in participating in treating liver diseases |
Q33563134 | The regulation of inflammatory mediators in acute kidney injury via exogenous mesenchymal stem cells. |
Q92394670 | Therapeutic Potential of Mesenchymal Stem Cells in Immune-Mediated Diseases |
Q52593734 | Therapeutic Use of Stem Cells for Myocardial Infarction. |
Q28076187 | Therapeutic use of stem cells for cardiovascular disease |
Q88601047 | Transplantation of adipose tissue-derived stem cells ameliorates autoimmune pathogenesis in MRL/lpr mice : Modulation of the balance between Th17 and Treg |
Q35844400 | Transplanted Umbilical Cord Mesenchymal Stem Cells Modify the In Vivo Microenvironment Enhancing Angiogenesis and Leading to Bone Regeneration |
Q35866047 | iPSC-MSCs Combined with Low-Dose Rapamycin Induced Islet Allograft Tolerance Through Suppressing Th1 and Enhancing Regulatory T-Cell Differentiation |
Search more.